Shinya Nakatani (Osaka　Metroporitan　University)

Mar 2006: Graduated from Wakayama Medical University

Apr 2006–Mar 2008: Junior Resident, Osaka City University Hospital

Apr 2008–Mar 2012: PhD Program, Osaka City University (Internal Medicine & Pathology)

2016–Present: Lecturer, Department of Nephrology (formerly Metabolism/Endocrinology), Osaka Metropolitan University

Autosomal Dominant Polycystic Kidney Disease (ADPKD): therapy and epidemiology

CKD–Mineral and Bone Disorder (CKD-MBD): vascular calcification

Nutrition: zinc metabolism and deficiency

Nakatani S, et al. Protocol for the nationwide registry of patients with polycystic kidney disease: Japanese national registry of PKD (JRP). Clin Exp Nephrol. 2024.

Nakatani S, et al. Short-Term Dapagliflozin Administration in Autosomal Dominant Polycystic Kidney Disease: A Retrospective Single-Arm Case Series Study.

Nakatani S, Ishimura E, Machiba Y, Nakatani A, Fujimoto K, Uedono M, et al. Novel Increasing Dose Regimen of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease in Patients with Low Tolerability. Nephrology (Carlton). 2018.

Morioka F*, Nakatani S* (co-first), et al. [Title]. J Clin Med. 2023.

Nakatani S, et al. Cinacalcet may suppress kidney enlargement in hemodialysis patients with autosomal dominant polycystic kidney disease. Sci Rep. 2021.